Indaptus Therapeutics, Inc. (INDP): Entry into a Material Definitive Agreement

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 8, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with the purchasers party thereto (collectively, the “ Purchasers ”), pursuant to which

Event · Offering · proposed
Instrument
common stock
Gross proceeds
$24.0 million
Shares
20,338,974 shares
Use of proceeds
working capital, research and development and other general corporate purposes

Facts are quoted from the filing text and checked against it.

Original reporting
Published Sep 10, 2026, 1:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 10:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$INDP
Neutral
high confidence
Mentioned
$INDP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INDPNeutralMed
01

Why it matters

The $24 M private placement funds immediate working capital and R&D, but introduces dilution risk.

02

Market read

Primary 8‑K disclosure of a capital raise; relevant for traders monitoring biotech micro‑caps.

03

What to watch

Potential future FDA submission timeline and competitive landscape for sleep‑related neuro‑devices.

Relevance 6/10Novelty 8/10Timing: Filed Sep 9 2026, effective immediately

Background

Indaptus Therapeutics is a clinical‑stage biotech developing a neuro‑technology device for sleep disorders.

Company-level read

Ticker impact

$INDPNeutralHigh confidence
Context

Indaptus Therapeutics filed an 8‑K announcing a private placement of 20.3M shares for $24 M gross proceeds.

Expected impact

Potential short‑term price dip on dilution, followed by stabilization as funds support R&D.

Evidence & confidence

Primary disclosure of a material equity raise; market typically reacts negatively to dilution but the cash infusion may support future milestones.

Market effects

Adds to biotech financing activity; may signal investor appetite for early‑stage neuro‑tech.

Limited to US biotech micro‑cap segment.

Low global impact.

Counterpoint

Dilution could be outweighed by accelerated R&D, making the stock a longer‑term buy.

Key entities

  • Indaptus Therapeutics, Inc.

    Issuer of the private placement.

  • Purchasers

    Unnamed investors acquiring the new shares.

Related articles

$INDPMed

Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (November 13, 2026) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, toda

$INDPMed

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today

$INDPMedAI 8/10

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics (Nasdaq: INDP) reported Q2 2026 results and a corporate update. It raised about $12.0 million via a June 17 private placement at $0.60 per share. The company discontinued further Decoy20 enrollment and has no active clinical programs. Q2 R&D fell to ~$0.4M and net loss to ~$1.8M. Cash and short-term investments were ~$11.6M at June 30.

$FFAIMed

Faraday Future (FFAI) Q3 2026 Earnings Call Transcript

Faraday Future (FFAI) reported Q3 2026 earnings, highlighting the October 23 acquisition of its robotics business by FFEAI Robotics Ecosystem (FFR) for $200M. FFAI now operates as an AI investment holding company, with FFR as a subsidiary. FFR, led by YT Jia, focuses on robotics, selling 351 devices in October. FFAI retains 66% ownership of FFR, which is included in consolidated financial statements.

$MARAMed

MARA Raises $185 Million to Fund Long Ridge Power Plant Deal

MARA raised $185 million via 8.750% senior secured notes due 2032 to fund its acquisition of Long Ridge Energy, a 505 MW gas plant. Proceeds will also repay part of Long Ridge's debt and cover fees. The offering is expected to close on November 27, 2026, alongside the acquisition. MARA has reduced its total debt by $1.4 billion in 2026 and authorized a $500 million share repurchase program.